Cargando…
Negative regulation of DAB2IP by Akt and SCF(Fbw7) pathways
Deletion of ovarian carcinoma 2/disabled homolog 2 (DOC-2/DAB2) interacting protein (DAB2IP), is a tumor suppressor that serves as a scaffold protein involved in coordinately regulating cell proliferation, survival and apoptotic pathways. DAB2IP is epigenetically down-regulated in a variety of tumor...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4102811/ https://www.ncbi.nlm.nih.gov/pubmed/24912918 |
_version_ | 1782327069809573888 |
---|---|
author | Dai, Xiangping North, Brian J. Inuzuka, Hiroyuki |
author_facet | Dai, Xiangping North, Brian J. Inuzuka, Hiroyuki |
author_sort | Dai, Xiangping |
collection | PubMed |
description | Deletion of ovarian carcinoma 2/disabled homolog 2 (DOC-2/DAB2) interacting protein (DAB2IP), is a tumor suppressor that serves as a scaffold protein involved in coordinately regulating cell proliferation, survival and apoptotic pathways. DAB2IP is epigenetically down-regulated in a variety of tumors through the action of the histone methyltransferase EZH2. Although DAB2IP is transcriptionally down-regulated in a variety of tumors, it remains unclear if other mechanisms contribute to functional inactivation of DAB2IP. Here we demonstrate that DAB2IP can be functionally down-regulated by two independent mechanisms. First, we identified that Akt1 can phosphorylate DAB2IP on S847, which regulates the interaction between DAB2IP and its effector molecules H-Ras and TRAF2. Second, we demonstrated that DAB2IP can be degraded in part through ubiquitin-proteasome pathway by SCF(Fbw7). DAB2IP harbors two Fbw7 phosho-degron motifs, which can be regulated by the kinase, CK1δ. Our data hence indicate that in addition to epigenetic down-regulation, two additional pathways can functional inactivate DAB2IP. Given that DAB2IP has previously been identified to possess direct causal role in tumorigenesis and metastasis, our data indicate that a variety of pathways may pass through DAB2IP to govern cancer development, and therefore highlight DAB2IP agonists as potential therapeutic approaches for future anti-cancer drug development. |
format | Online Article Text |
id | pubmed-4102811 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-41028112014-07-23 Negative regulation of DAB2IP by Akt and SCF(Fbw7) pathways Dai, Xiangping North, Brian J. Inuzuka, Hiroyuki Oncotarget Research Paper Deletion of ovarian carcinoma 2/disabled homolog 2 (DOC-2/DAB2) interacting protein (DAB2IP), is a tumor suppressor that serves as a scaffold protein involved in coordinately regulating cell proliferation, survival and apoptotic pathways. DAB2IP is epigenetically down-regulated in a variety of tumors through the action of the histone methyltransferase EZH2. Although DAB2IP is transcriptionally down-regulated in a variety of tumors, it remains unclear if other mechanisms contribute to functional inactivation of DAB2IP. Here we demonstrate that DAB2IP can be functionally down-regulated by two independent mechanisms. First, we identified that Akt1 can phosphorylate DAB2IP on S847, which regulates the interaction between DAB2IP and its effector molecules H-Ras and TRAF2. Second, we demonstrated that DAB2IP can be degraded in part through ubiquitin-proteasome pathway by SCF(Fbw7). DAB2IP harbors two Fbw7 phosho-degron motifs, which can be regulated by the kinase, CK1δ. Our data hence indicate that in addition to epigenetic down-regulation, two additional pathways can functional inactivate DAB2IP. Given that DAB2IP has previously been identified to possess direct causal role in tumorigenesis and metastasis, our data indicate that a variety of pathways may pass through DAB2IP to govern cancer development, and therefore highlight DAB2IP agonists as potential therapeutic approaches for future anti-cancer drug development. Impact Journals LLC 2014-05-01 /pmc/articles/PMC4102811/ /pubmed/24912918 Text en Copyright: © 2014 Dai et al. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Paper Dai, Xiangping North, Brian J. Inuzuka, Hiroyuki Negative regulation of DAB2IP by Akt and SCF(Fbw7) pathways |
title | Negative regulation of DAB2IP by Akt and SCF(Fbw7) pathways |
title_full | Negative regulation of DAB2IP by Akt and SCF(Fbw7) pathways |
title_fullStr | Negative regulation of DAB2IP by Akt and SCF(Fbw7) pathways |
title_full_unstemmed | Negative regulation of DAB2IP by Akt and SCF(Fbw7) pathways |
title_short | Negative regulation of DAB2IP by Akt and SCF(Fbw7) pathways |
title_sort | negative regulation of dab2ip by akt and scf(fbw7) pathways |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4102811/ https://www.ncbi.nlm.nih.gov/pubmed/24912918 |
work_keys_str_mv | AT daixiangping negativeregulationofdab2ipbyaktandscffbw7pathways AT northbrianj negativeregulationofdab2ipbyaktandscffbw7pathways AT inuzukahiroyuki negativeregulationofdab2ipbyaktandscffbw7pathways |